OCTREOTIDE DESTINE A ETRE ADMINISTRE PAR VOIE ORALE EN ASSOCIATION AVEC D'AUTRES AGENTS THERAPEUTIQUES

• 收藏
• 分享

专利权人:

GELBAUM, DANA;MAMLUK, RONI;CHIASMA INC.

发明人:

HAVIV, ASI,MAMLUK, RONI,GELBAUM, DANA

申请号：

CA2970519

公开号：

CA2970519A1

申请日:

2015.12.10

申请国别(地区):

CA

年份:

2016

代理人:

摘要：

This invention relates to combination therapy of a subject suffering from acromegaly. The method of treatment comprises administration to the subject of a therapeutically effective amount of oral somatostatin receptor ligand (SRL) e.g. octreotide in combination with a therapeutically effective amount of a dopamine agonist and/or a growth hormone receptor antagonist and/or a selective estrogen receptor modulator (SERM) and/or a 2nd somatostatin receptor ligand (SRL).

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/